Interim Financial Statements (Tables)

3 Months Ended

Mar. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]

The following tables summarize the impacts of adopting ASC 606 on the Company's condensed consolidated financial statements for the three months ended March 31, 2018 as compared with the guidance that was in effect before the change.

	March 31, 2018
Balance Sheet Data	As Reported		Adjustments			Balance Without Adoption of ASC 606
Deferred tax assets	$	532,268	$	(18,206	)	$	514,062
Total assets	$	9,372,696	$	(18,206	)	$	9,354,490
Accrued expenses and other current liabilities	$	666,216	$	(1,513	)	$	664,703
Deferred revenue from Sanofi (current)	$	231,447	$	(33,632	)	$	197,815
Deferred revenue - other (current)	$	160,466	$	(69,241	)	$	91,225
Total current liabilities	$	1,265,740	$	(104,386	)	$	1,161,354
Deferred revenue from Sanofi (noncurrent)	$	406,778	$	(51,604	)	$	355,174
Deferred revenue - other (noncurrent)	$	257,967	$	18,277		$	276,244
Total liabilities	$	2,805,052	$	(137,713	)	$	2,667,339
Retained earnings	$	3,287,767	$	119,507		$	3,407,274
Total stockholders' equity	$	6,567,644	$	119,507		$	6,687,151
Total liabilities and stockholders' equity	$	9,372,696	$	(18,206	)	$	9,354,490

	Three Months Ended March 31, 2018
Consolidated Statement of Operations Data	As Reported			Adjustments			Balance Without Adoption of ASC 606
Sanofi collaboration revenue	$	189,490		$	(8,407	)	$	181,083
Other revenue	$	86,158		$	(17,310	)	$	68,848
Total revenues	$	1,511,485		$	(25,717	)	$	1,485,768
Income from operations	$	567,231		$	(25,717	)	$	541,514
Income before income taxes	$	585,398		$	(25,717	)	$	559,681
Income tax expense	$	(107,418	)	$	1,789		$	(105,629	)
Net income	$	477,980		$	(23,928	)	$	454,052